Abstract:Pulmonary sarcomatoid carcinoma (PSC) is a kind of rare non-small cell lung cancer (NSCLC) with insidious symptoms, strong invasiveness, insensitiveness to traditional treatments and poor prognosis. With the development of molecular typing and liquid biopsy techniques in recent years, the molecular biological characteristics of PSC have been understanded deeply. Furthermore, the clinical efficacy has been significantly improved owing to novel molecular targeting therapeutic and immunotherapeutic agents. Based on the recent advances in the management of PSC, this article especially focuses on the progress on molecular targeted therapy and immunotherapy in order to provide some reference for clinical practice.